Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genprex ( (GNPX) ) has provided an update.
On November 19, 2025, Genprex announced the addition of Gabrail Cancer Center in Canton, Ohio, as a new site for its Acclaim-1 and Acclaim-3 clinical trials. These trials are evaluating Reqorsa® Gene Therapy in combination with other treatments for lung cancer. The company plans to expand its clinical trial sites to increase patient reach and expedite enrollment. The Acclaim-1 trial, which targets non-small cell lung cancer, has shown promising early results and received FDA Fast Track Designation. Acclaim-3 focuses on small cell lung cancer and is supported by both FDA Fast Track and Orphan Drug Designations. These developments are expected to enhance Genprex’s position in the oncology sector by advancing its clinical trials and potentially improving treatment options for lung cancer patients.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for cancer and diabetes. Its primary product is the Reqorsa® Gene Therapy, which is being studied in clinical trials for lung cancer treatment.
Average Trading Volume: 775,112
Technical Sentiment Signal: Sell
Current Market Cap: $9.17M
For detailed information about GNPX stock, go to TipRanks’ Stock Analysis page.